# US 5,352,449 A · Vaccine comprising recombinant feline leukemia antigen and saponin adjuvant

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 5,352,449 A
- Document ID: US5352449A
- Status: Granted
- Kind: A
- Application number: 07/869,082
- Filed: 1992-04-14
- Granted: 1994-10-04
- Earliest claimed: 1986-05-30
- Assignees: Cambridge Biotech Corporation
- Inventors: Gerald A. Beltz; Dante J. Marciani; Chung-Ho Hung; Charlotte A. Kensil
- Web page: https://patentgrep.com/patent/US5352449A

## CPC

- C07K 14/005: from viruses
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- C12N 2740/13022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- Y10S 424/819: Viral vaccine for feline species, e.g. cats
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- Y10S: TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS

## Abstract

The invention relates to antigenic preparations useful for inducing the production of antibodies in a cat which will bind to epitopes on feline leukemia virus. Also disclosed are immunogenic compositions and methods for immunizing a cat to enable the production of antibodies to feline leukemia virus.

## Claims

### Claim 1

A vaccine capable of protecting a cat against feline leukemia vira (FeLV) comprising an immunogenically effective amount of FeLV subgroup A recombinant gp70 together with a substantially pure saponin adjuvant selected from the group consisting of QA-7, QA-17, QA-18, and QA-21.

### Claim 2

A vaccine capable of protecting a cat against feline leukemia vira (FeLV) comprising an immunogenically effective amount of FeLV subgroup A recombinant gp70-delta together with a substantially pure saponin adjuvant selected from the group consisting of QA-7, QA-17, QA-18, and QA-21.

### Claim 3

A vaccine capable of protecting a cat against feline leukemia vira (FeLV) comprising an immunogenically effective amount of FeLV subgroup A recombinant gp90 together with a substantially pure saponin adjuvant selected from the group consisting of QA-7, QA-17, QA-18, and QA-21.

### Claim 4 (depends on 1, 2, 3)

The vaccine of any one of claims 1-3, wherein the saponin adjuvant is QA-7.

### Claim 5 (depends on 1, 2, 3)

The vaccine of any one of claims 1-3, wherein the saponin adjuvant is QA-17.

### Claim 6 (depends on 1, 2, 3)

The vaccine of any one of claims 1-3, wherein the saponin adjuvant is QA-18.

### Claim 7 (depends on 1, 2, 3)

The vaccine of any one of claims 1-3, wherein the saponin adjuvant is QA-21.

### Claim 8 (depends on 1, 2, 3)

The vaccine of any one of claims 1-3, further comprising aluminum hydroxide.

### Claim 9

A vaccine capable of protecting a cat against feline leukemia virus (FeLV) comprising an immunogenically effective amount of FeLV subgroup A recombinant gp70-delta together with saponin adjuvant QA-21 and aluminum hydroxide.